drugset / Trial / NCT01871961

Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient

NCT01871961

Phase 1 Completed 105 enrolled medac GmbH PPD Development, LP · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the human factors/usability of Rheumatoid Arthritis (RA) patients with the Metoject® prefilled pen (including a label comprehension assessment and a device robustness evaluation).

Timeline

Start
2012-10
Primary completion
2013-02
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule Subcutaneous

Indications